Phase II randomised, double-blind, multicentre, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of 3 strengths of AD 452 in adults with active RA [rheumatoid arthritis] who are currently taking methotrexate
Latest Information Update: 21 Jul 2011
At a glance
- Drugs AD 452 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Sosei
- 23 Nov 2006 Status change
- 15 Nov 2006 Status change
- 21 Oct 2005 New trial record.